[1] 赵峰,苗怡然,曹生亚.吉非替尼对EGFR敏感突变肺腺癌脑转移 患者的预后影响[J].肿瘤学杂志,2018,24(3):221-225. [2] 王昆,黄云超,赵光强,等.2013-2014年云南省肿瘤医院收治肺 癌患者的临床流行病学特征[J].云南医药,2016,37(2):246-249. [3] Nahar R, Zhai W, Zhang T,etal. Elucidating the genom-ic architecture of Asian EGFR-mutant lung adenocarcino-ma through multi-region exome sequencing [J]. Nat Com-mun,2018,9(1):216-225. [4] Wang Z, Wu Y, Zhang G,et al. VEGF-D expression in lung adenocarcinoma with or without acquired resistance to gefitinib and normal lung tissue [J]. Chin J Lung Cancer, 2007,10(6):477-480. [5] Cui J, Zhang Y, Su D,et al. Efficacy of combined icotinib and pemetrexed in EGFR mutant lung adenocarcinoma cell line xenografts: Ico & Pem efficacy in HCC827 xenografts [J]. Thoracic Cancer, 2018,9(9):1-10. [6] 陈文福.AC方案联合吉非替尼序贯治疗EGFR基因敏感突变的 肺腺癌患者的临床疗效观察[J].实用癌症杂志,2018,33(10): 1651-1654,1658. [7] Wu YL, Saijo N, Thongprasert S,et al. Efficacy accord-ing to blind independent central review: Post-hoc analyses from the phase Ⅲ, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation- positive advanced NSCLC [J]. Lung Cancer, 2017,104(Complete):119-125. [8] Wu YL, Lee V, Liam CK,et al. Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT- 2, and ASPIRATION studies [J]. Lung Cancer, 2018,126(1): 1-8. [9] Lee JM, Mao JT, Krysan K,et al. Significance of cyclo-oxygenase-2 in prognosis, targeted therapy and chemopre-vention of NSCLC [J]. Future Oncol,2007,3(2):149-153. [10] Suqawara S, Oizumi S, Minato K, et al. Randomized phaseⅡstudy of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902[J]. Ann Oncol, 2015,26(5):888-894. [11] 邵青.肺癌患者生活质量测评方法及相关因素分析的研究进展 [J].重庆医学,2014,43(3):352-355